|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy显示文摘Hepatitis due to hepatitis B virus(HBV) reactivation can be severe and potentially fatal, but is preventable. HBV reactivation is most commonly reported in patients receiving cancer chemotherapy, especially rituximabcontaining therapy for hematological malignancies and those receiving stem cell transplantation. All patients with hematological malignancies receiving anticancer therapy should be screened for active or resolved HBV infection by blood tests for hepatitis B surface antigen(HBs Ag) and antibody to hepatitis B core antigen(antiHBc). Patients found to be positive for HBs Ag should be given prophylactic antiviral therapy to prevent HBV reactivation. For patients with resolved HBV infection, no standard strategy has yet been established to prevent HBV reactivation. There are usually two options. One is pre-emptive therapy guided by serial HBV DNA monitoring, whereby antiviral therapy is given as soon as HBV DNA becomes detectable. However, there is little evidence regarding the optimal interval and period of monitoring. An alternative approach is prophylactic antiviral therapy, especially for patients receiving highrisk therapy such as rituximab, newer generation of anti-CD20 monoclonal antibody, obinutuzumab or hematopoietic stem cell transplantation. This strategy may effectively prevent HBV reactivation and avoid the inconvenience of repeated HBV DNA monitoring. Entecavir or tenofovir are preferred over lamivudine as prophylactic therapy. Although there is no well-defined guideline on the optimal duration of prophylactic therapy, there is growing evidence to recommend continuing prophylactic antiviral therapy for at least 12 mo after cessation of chemotherapy, and even longer for those who receive rituximab or who had high serum HBV DNA levels before the start of immunosuppressive therapy. Many novel agents have recently become available for the treatment of hematological malignancies, and these agents may be associated with HBV reactivation. Although there is currently limited evidence to guide the optimal preventive measures, we recommend antiviral prophylaxis in HBs Ag-positive patients receiving novel treatments, especially the Bruton tyrosine kinase inhibitors and the phosphatidylinositol 3-kinase inhibitors, which are B-cell receptor signaling modulators and reduce proliferation of malignant B-cells. Further studies are needed to clarify the risk of HBV reactivation with these agents and the best prophylactic strategy in the era of targeted therapy for hematological malignancies. | Man Fai Law Rita Ho Carmen KM Cheung Lydia HP Tam Karen Ma Kent CY So Bonaventure Ip Jacqueline So Jennifer Lai Joyce Ng Tommy HC Tam | 2016 | World Journal of Gastroenterology2016，22，28： | 10 |
| 2 | What are the ten new commandments in severe polytrauma management?显示文摘 | CW Kam CH Lai SK Lam FL So CL Lau KH Cheung | 2010 | World Journal of Emergency Medicine2010，1，2： | 9 |
| 3 | Effectiveness of noninvasive positive pressure ventilation in the treatment of acute respiratory failure in severe acute respiratory syndrome to treats severe 显示文摘 | Cheung TM Yam LY So LK | 2004 | Chest2004，126，： | 1 |
| 4 | Lithium chloride reinforces the regeneration-promoting effect of chondroitinase ABC on rubrospinal neurons after spinal cord injury显示文摘 | So KF Cheung PT | 2004 | J Neurotrauma2004，21，7： | 1 |
| 5 | An Improved DV-Hop Localization Algorithm with Reduced Node location Error for Wireless Sensor Networks显示文摘 | Hongyang CHEN Kaoru SEZAKI PingDENG and Hing Cheung SO | 2008 | Communacations and Computer Sciences2008，91，8： | 1 |
| 6 | Interleukin - 10 inhibits lipopolysaccharide induced miR - 155 precursor stability and maturation显示文摘 | Cheung ST So EY Chang D | 2013 | PLoS One2013，8，71： | 1 |
| 7 | Least squares algorithms for time-of-arrival-based mobile location显示文摘 | CHEUNG K W SO H C MA W K | 2004 | IEEE Trans on Signal Processing2004，52，4： | 1 |
| 8 | Least squares algorithms for time-of-arrival-based mobile location显示文摘 | Cheung K W So H C Ma W K | 2004 | IEEE Transactions on Signal Processing2004，53，4： | 1 |
| 9 | An automated partnering monitoring systempartnering temperature index显示文摘 | Cheung SO Suen HCH Cheung KKW | | Automat Constr0，200，： | 1 |
| 10 | Subspace-Based Algorithm for Parameter Estimation of Polynomial Phase Signals显示文摘 | Yuntao Wu hing Cheung So Hongqing Liu | 2008 | IEEE Transactions on Signal Processing2008，56，10： | 1 |
| 11 | A Constrained Least Squares Approach to Mobile Positioning: Algorithms and Optimality显示文摘 | Cheung K W So H C Ma W K | 2006 | Eurasip Journal on Applied Signal Processing2006，，17： | 1 |
| 12 | Least squares algorithms for time-of-arrival-based mobile location显示文摘 | CHEUNG K W SO H C MAW K | | 0，，04： | 1 |
| 13 | Gene expression patterns in human liver cancers显示文摘 | Chen X Cheung S T So S | 2002 | Mol Biol Cell2002，13，6： | 1 |
| 14 | Axonal regeneration of Clarke′s neurons beyond the spinal cord injury scar after treatment with chondroitinase ABC 显示文摘 | Yick LW Cheung PT So KF | 2003 | Exp Neurol2003，182，1： | 1 |
| 15 | Gene expression pattems in human liver cancers 显示文摘 | Chen X Cheung S T So S | 2002 | Mol Biol Cell2002，13，6： | 1 |
| 16 | Bone marrow in- volvement by nasal NK cell lymphoma at diagnosis is uncommon 显示文摘 | WongK F Chan J K Cheung M M So J C | 2001 | Am J Clin Pathol2001，115，2： | 1 |
| 17 | Least squares al- gorithms for time-of-arrival-based mobile location 显示文摘 | Cheung K W So H C Ma W K | 2004 | IEEE Transactions on Signal Processing2004，52，4： | 1 |
| 18 | A multidimensional scaling framework for mobile location using time-of-arrival measurements显示文摘 | CHEUNG K W SO H C | 2005 | IEEE Trans Signal Process2005，53，4： | 1 |
| 19 | Development of a standard treatment protocol for severe acute respiratory syndrome 显示文摘 | So LK Lau AC Yam LY Cheung TM Poon E Yung RW Yuen KY | 2003 | Lancet 2003 102003，361，9369： | 1 |
| 20 | Are construction disputes inevitable?显示文摘 | Cheung SO Yiu T W | 2006 | Engineer Management2006，52，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员